Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
Oncotarget. 2024 Feb 22;15:142. doi: 10.18632/oncotarget.28523.NO ABSTRACTPMID:38386812 | PMC:PMC10883681 | DOI:10.18632/oncotarget.28523 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Maryam Zanjirband Nicola Curtin Richard J Edmondson John Lunec Source Type: research

Correction: YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model
Oncotarget. 2024 Feb 22;15:143. doi: 10.18632/oncotarget.28524.NO ABSTRACTPMID:38386842 | PMC:PMC10883682 | DOI:10.18632/oncotarget.28524 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Tsion Zewdu Minas Jenny Han Tahereh Javaheri Sung-Hyeok Hong Michaela Schlederer Yasemin Saygide ğer-Kont Haydar Çelik Kristina M Mueller Idil Temel Metin Özdemirli Heinrich Kovar Hayriye Verda Erkizan Jeffrey Toretsky Lukas Kenner Richard Moriggl Ayku Source Type: research

Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas
Oncotarget. 2024 Feb 22;15:144-158. doi: 10.18632/oncotarget.28559.ABSTRACTSacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker. SG has received United States Food and Drug Administration (FDA) approval to treat metastatic triple-negative breast cancer (TNBC), unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and accelerated approval for metastatic urothelial cancer. We investigated...
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Thomas M Cardillo Maria B Zalath Roberto Arrojo Robert M Sharkey Serengulam V Govindan Chien-Hsing Chang David M Goldenberg Source Type: research

Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health
CONCLUSIONS: This study reveals that the prevalence of germline mutations in the BRCA1 and BRCA2 genes was higher than reported by other studies. A broader understanding of the prevalence and role of BRCA mutations in development, response to treatment, and prognosis represents an exciting and developing area of ovarian cancer treatment and prevention.PMID:38386807 | PMC:PMC10883683 | DOI:10.18632/oncotarget.28561 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Elisabetta De Matteis Maria Rosaria Tumolo Paolo Tarantino Mariangela Ciccarese Tiziana Grassi Francesco Bagordo Maria Rita De Giorgio Emanuele Rizzo Graziana Ronzino Source Type: research

Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
Oncotarget. 2024 Feb 22;15:142. doi: 10.18632/oncotarget.28523.NO ABSTRACTPMID:38386812 | PMC:PMC10883681 | DOI:10.18632/oncotarget.28523 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Maryam Zanjirband Nicola Curtin Richard J Edmondson John Lunec Source Type: research

Correction: YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model
Oncotarget. 2024 Feb 22;15:143. doi: 10.18632/oncotarget.28524.NO ABSTRACTPMID:38386842 | PMC:PMC10883682 | DOI:10.18632/oncotarget.28524 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Tsion Zewdu Minas Jenny Han Tahereh Javaheri Sung-Hyeok Hong Michaela Schlederer Yasemin Saygide ğer-Kont Haydar Çelik Kristina M Mueller Idil Temel Metin Özdemirli Heinrich Kovar Hayriye Verda Erkizan Jeffrey Toretsky Lukas Kenner Richard Moriggl Ayku Source Type: research

Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas
Oncotarget. 2024 Feb 22;15:144-158. doi: 10.18632/oncotarget.28559.ABSTRACTSacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker. SG has received United States Food and Drug Administration (FDA) approval to treat metastatic triple-negative breast cancer (TNBC), unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and accelerated approval for metastatic urothelial cancer. We investigated...
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Thomas M Cardillo Maria B Zalath Roberto Arrojo Robert M Sharkey Serengulam V Govindan Chien-Hsing Chang David M Goldenberg Source Type: research

Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health
CONCLUSIONS: This study reveals that the prevalence of germline mutations in the BRCA1 and BRCA2 genes was higher than reported by other studies. A broader understanding of the prevalence and role of BRCA mutations in development, response to treatment, and prognosis represents an exciting and developing area of ovarian cancer treatment and prevention.PMID:38386807 | PMC:PMC10883683 | DOI:10.18632/oncotarget.28561 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Elisabetta De Matteis Maria Rosaria Tumolo Paolo Tarantino Mariangela Ciccarese Tiziana Grassi Francesco Bagordo Maria Rita De Giorgio Emanuele Rizzo Graziana Ronzino Source Type: research

Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
Oncotarget. 2024 Feb 22;15:142. doi: 10.18632/oncotarget.28523.NO ABSTRACTPMID:38386812 | PMC:PMC10883681 | DOI:10.18632/oncotarget.28523 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Maryam Zanjirband Nicola Curtin Richard J Edmondson John Lunec Source Type: research

Correction: YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model
Oncotarget. 2024 Feb 22;15:143. doi: 10.18632/oncotarget.28524.NO ABSTRACTPMID:38386842 | PMC:PMC10883682 | DOI:10.18632/oncotarget.28524 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Tsion Zewdu Minas Jenny Han Tahereh Javaheri Sung-Hyeok Hong Michaela Schlederer Yasemin Saygide ğer-Kont Haydar Çelik Kristina M Mueller Idil Temel Metin Özdemirli Heinrich Kovar Hayriye Verda Erkizan Jeffrey Toretsky Lukas Kenner Richard Moriggl Ayku Source Type: research

Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas
Oncotarget. 2024 Feb 22;15:144-158. doi: 10.18632/oncotarget.28559.ABSTRACTSacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker. SG has received United States Food and Drug Administration (FDA) approval to treat metastatic triple-negative breast cancer (TNBC), unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and accelerated approval for metastatic urothelial cancer. We investigated...
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Thomas M Cardillo Maria B Zalath Roberto Arrojo Robert M Sharkey Serengulam V Govindan Chien-Hsing Chang David M Goldenberg Source Type: research

Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health
CONCLUSIONS: This study reveals that the prevalence of germline mutations in the BRCA1 and BRCA2 genes was higher than reported by other studies. A broader understanding of the prevalence and role of BRCA mutations in development, response to treatment, and prognosis represents an exciting and developing area of ovarian cancer treatment and prevention.PMID:38386807 | PMC:PMC10883683 | DOI:10.18632/oncotarget.28561 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Elisabetta De Matteis Maria Rosaria Tumolo Paolo Tarantino Mariangela Ciccarese Tiziana Grassi Francesco Bagordo Maria Rita De Giorgio Emanuele Rizzo Graziana Ronzino Source Type: research

Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
Oncotarget. 2024 Feb 22;15:142. doi: 10.18632/oncotarget.28523.NO ABSTRACTPMID:38386812 | PMC:PMC10883681 | DOI:10.18632/oncotarget.28523 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Maryam Zanjirband Nicola Curtin Richard J Edmondson John Lunec Source Type: research

Correction: YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model
Oncotarget. 2024 Feb 22;15:143. doi: 10.18632/oncotarget.28524.NO ABSTRACTPMID:38386842 | PMC:PMC10883682 | DOI:10.18632/oncotarget.28524 (Source: Oncotarget)
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Tsion Zewdu Minas Jenny Han Tahereh Javaheri Sung-Hyeok Hong Michaela Schlederer Yasemin Saygide ğer-Kont Haydar Çelik Kristina M Mueller Idil Temel Metin Özdemirli Heinrich Kovar Hayriye Verda Erkizan Jeffrey Toretsky Lukas Kenner Richard Moriggl Ayku Source Type: research

Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas
Oncotarget. 2024 Feb 22;15:144-158. doi: 10.18632/oncotarget.28559.ABSTRACTSacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker. SG has received United States Food and Drug Administration (FDA) approval to treat metastatic triple-negative breast cancer (TNBC), unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and accelerated approval for metastatic urothelial cancer. We investigated...
Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Thomas M Cardillo Maria B Zalath Roberto Arrojo Robert M Sharkey Serengulam V Govindan Chien-Hsing Chang David M Goldenberg Source Type: research